← Back to Search

Herbal Medicine

Therapeutic Effect of Chinese Herbal Medicine on Food Allergy (FAHF-2 Trial)

Phase 2
Waitlist Available
Led By Julie Wang, M.D.
Research Sponsored by Li, Xiu-Min, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.

Eligible Conditions
  • Food Allergy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 1Active Control1 Intervention
2 different dosages
Group II: 2Placebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Li, Xiu-Min, M.D.Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)NIH
862 Previous Clinical Trials
674,033 Total Patients Enrolled
2 Trials studying Food Allergy
104 Patients Enrolled for Food Allergy
Julie Wang, M.D.Principal InvestigatorIcahn School of Medicine at Mount Sinai
Xiu-Min LiStudy DirectorIcahn School of Medicine at Mount Sinai
~4 spots leftby Dec 2025